Publications by Georgios Sflomos

Related publications (16)

A novel culture method that sustains ER alpha signaling in human breast cancer tissue microstructures

Background Estrogen receptor alpha (ER alpha) signaling is a defining and driving event in most breast cancers; ER alpha is detected in malignant epithelial cells of 75% of all breast cancers (classified as ER-positive breast cancer) and, in these cases, E ...

2020

Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast

Cathrin Brisken, Georgios Sflomos, Ayyakkannu Ayyanan, Tamara Tanos

Estrogens and progesterones are major drivers of breast development but also promote carcinogenesis in this organ. Yet, their respective roles and the mechanisms underlying their action in the human breast are unclear. Receptor activator of nuclear factor ...

American Association for the Advancement of Science2013

Oestrogen receptor alpha AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium

Cathrin Brisken, Georgios Sflomos, Valentina Scabia, Patrik Aouad, Ayyakkannu Ayyanan, Dalya Ataca, Stéphanie Cagnet

Oestrogen receptor alpha (ER alpha) is a transcription factor with ligand-independent and ligand-dependent activation functions (AF)-1 and -2. Oestrogens control postnatal mammary gland development acting on a subset of mammary epithelial cells (MECs), ter ...

Nature Publishing Group2018

Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions

Cathrin Brisken, Valentina Scabia, Georgios Sflomos, Laura Battista, Ayyakkannu Ayyanan, Valérian Charles Robert Dormoy, Patrik Aouad

Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to establish as patient-derived xenografts (PDXs). We and others recently demonstrated that the microenvironment is critical for ER-positive tumor cells; when ...

2018

Is There a Special Role for Ovarian Hormones in the Pathogenesis of Lobular Carcinoma?

Cathrin Brisken, Georgios Sflomos

Lobular carcinoma represent the most common special histological subtype of breast cancer, with the majority classed as hormone receptor positive. Rates of invasive lobular carcinoma in postmenopausal women have been seen to increase globally, while other ...

Endocrine Soc2024

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma

Cathrin Brisken, Georgios Sflomos, Laura Battista

Simple Summary Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and is often detected at an advanced stage. Up to 30% of ILC cases relapse and present a challenge for treatment. Unfortunately, there are few mod ...

MDPI2023

Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1

Philipp Bucher, Cathrin Brisken, Giovanna Ambrosini, Georgios Sflomos, Valentina Scabia, Patrik Aouad, Laura Battista, Fabio De Martino, Ayyakkannu Ayyanan

Invasive lobular carcinoma (ILC) is the most frequent special histological subtype of breast cancer, typically characterized by loss of E‐cadherin. It has clinical features distinct from other estrogen receptor‐positive (ER+) breast cancers but the molecul ...

2021

Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer

Georgios Sflomos

Targeting aromatase deprives ER(+ )breast cancers of estrogens and is an effective therapeutic approach for these tumors. However, drug resistance is an unmet clinical need. Lipidomic analysis of long-term estrogen-deprived (LTED) ER+ breast cancer cells, ...

2024

Patient-derived xenograft (PDX) models in basic and translational breast cancer research

Cathrin Brisken, Georgios Sflomos, Valentina Scabia

Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now ...

Springer Verlag2016

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response

Cathrin Brisken, Georgios Sflomos, Ayyakkannu Ayyanan, Valentina Scabia, Rachel Marcone, Laura Battista, Valérian Charles Robert Dormoy

Seventy-five percent of breast cancers are estrogen receptor α positive (ER(+)). Research on these tumors is hampered by lack of adequate in vivo models; cell line xenografts require non-physiological hormone supplements, and patient-derived xenografts (PD ...

Elsevier2016

Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence

Céline Marie Victoria Stibolt, Cathrin Brisken, Giovanna Ambrosini, Georgios Sflomos, Patrik Aouad, Fabio De Martino, Yueyun Zhang, Kelly Spry Maggs, Hazel Margaret Quinn

More than 70% of human breast cancers (BCs) are estrogen receptor α-positive (ER+). A clinical challenge of ER+ BC is that they can recur decades after initial treatments. Mechanisms governing latent disease remain elusive due to lack of adequate in vivo m ...

Nature Research2022

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity

Cathrin Brisken, Georgios Sflomos, Laura Battista

Functional studies giving insight into the biology of circulating tumor cells (CTCs) remain scarce due to the low frequency ofCTCs and lack of appropriate models. Here, we describe the characterization of a novelCTC-derived breast cancer cell line, designa ...

2020

Novel human cell line xenograft models of ER alpha-positive metastatic invasive lobular breast carcinoma as pre-clinical platforms for validating candidate genetic drivers

Jeremy Luterbacher, Cathrin Brisken, Georgios Sflomos, Wenhao Hou

AMER ASSOC CANCER RESEARCH2019